Zeria Pharmaceutical Co., Ltd.

4559

JP3428850006

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
2,059 ^JPY	+0.54%		+0.88%	+2.08%

Apr. 23	Borsch Med Pte. Ltd. Introduces Chondroitin Supplements of Zeria Pharmaceutical Co. Ltd to Singapore for Healthy Joints	CI
Feb. 16	Zeria Pharmaceutical's Profit Up 41% in Fiscal Q1-Q3	MT

Zeria Pharmaceutical Co., Ltd. entered into an agreement to acquire Nissui Pharm Medical Sales Co., Ltd. from Nissui Pharmaceutical Co., Ltd. for ¥3.3 billion.

January 16, 2020

Zeria Pharmaceutical Co., Ltd. (TSE:4559) entered into an agreement to acquire Nissui Pharm Medical Sales Co., Ltd. from Nissui Pharmaceutical Co., Ltd. (TSE:4550) for ¥3.3 billion on January 17, 2020. As part of the transaction, Nissui Pharmaceutical Co., Ltd. will transfer its entire stake in Nissui Pharm Medical Sales Co., Ltd. representing 5000 shares. The transaction is expected to complete on April 1, 2020.

Latest news about Zeria Pharmaceutical Co., Ltd.

Borsch Med Pte. Ltd. Introduces Chondroitin Supplements of Zeria Pharmaceutical Co. Ltd to Singapore for Healthy Joints	Apr. 23	CI
Zeria Pharmaceutical's Profit Up 41% in Fiscal Q1-Q3	Feb. 16	MT
Japanese Shares End Firmer on Friday on BoJ Policy Outlook	Nov. 17	MT
Zeria Pharmaceutical Books Higher Fiscal H1 Attributable Profit on Loss Provision Reversal	Nov. 16	MT
Zeria Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter of Fiscal Year Ending March 31, 2024, Payable on December 1, 2023	Nov. 15	CI
Zeria Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2024	Nov. 15	CI
Zeria Pharmaceutical’s Attributable Profit Up 12.1% in Fiscal Q1 on Absence of Forex Losses	23-08-22	MT
Zeria Pharmaceutical Co., Ltd. Provides Dividend Forecast for the Fiscal Year Ending March 31, 2024	23-08-21	CI
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for the Six Months of 2024 and the Fiscal Year Ending March 31, 2024	23-08-21	CI
Zeria Pharmaceutical Co., Ltd. Provides Dividend Forecast for the Second Quarter of 2024	23-08-21	CI
Tranche Update on Zeria Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2022.	23-05-16	CI
Zeria Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 11, 2022, has closed with 263,900 shares, representing 0.6% for ¥545.29 million.	23-05-11	CI
Zeria Pharmaceutical Co., Ltd. Provides Year End Dividend Guidance for the Full Year Ending March 31, 2024	23-05-11	CI
Zeria Pharmaceutical Co., Ltd. Announces Year End Dividend for the Full Year Ending March 31, 2023, Payable on June 30, 2023; Provides Second Quarter Dividend Guidance for the Full Year Ending March 31, 2024	23-05-11	CI
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Six Months and Full Year Ending March 31, 2024	23-05-11	CI
Tranche Update on Zeria Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2022.	23-04-04	CI
Zeria Pharmaceutical's Attributable Profit Soars 48% in Fiscal Nine Months	23-02-21	MT
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023	23-02-02	CI
Zeria Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2023	23-02-02	CI
Tranche Update on Zeria Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2022.	23-01-06	CI
Zeria Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2023	22-11-02	CI
Zeria Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter of the Year Ending March 31, 2023, Payable on December 1, 2022	22-11-02	CI
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023	22-11-02	CI
Zeria Pharmaceutical Co., Ltd.'s Equity Buyback Plan Extended till May 12, 2023.	22-11-01	CI
Tranche Update on Zeria Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2022.	22-10-04	CI

Chart Zeria Pharmaceutical Co., Ltd.

Duration

Period

More charts

Company Profile

Zeria Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the development of ethical drug business, consumer healthcare business and other business. The Company operates in two business segments. The Ethical Drug segment is engaged in the research, development, manufacture and sale of ethical drugs. The Consumer Healthcare segment is engaged in the manufacture, purchase and sale of over-the-counter (OTC) drugs, health foods, quasi drugs and cosmetics related to self-medication. The others include insurance agency business and real estate business, as well as various maintenance business such as purchasing and sale of promotional materials.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Zeria Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2,059 JPY

Average target price

2,810 JPY

Spread / Average Target

+36.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ZERIA PHARMACEUTICAL CO., LTD.	+2.08%	580M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.78B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.89B
SANDOZ GROUP AG	+10.86%	14.45B
CIPLA LIMITED	+13.07%	13.63B
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.49B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.85B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+6.35%	5.06B

Generic Pharmaceuticals